Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy

Overview

Journal Cancer Res

Specialty Oncology

Date 2024 Apr 8

PMID 38588411

Authors

Sean Murphy

Sharif Rahmy

Dailin Gan

Guoqiang Liu

Yini Zhu

Maxim Manyak

Loan Duong

Jianping He

James H Schofield

Zachary T Schafer

Jun Li

Xuemin Lu

Xin Lu

Affiliations

Soon will be listed here.

Abstract

Significance: Optimized cyclic ketogenic diet and 1,3-butanediol supplementation regimens enhance the efficacy of immune checkpoint blockade in prostate cancer through epigenetic and immune modulations, providing dietary interventions to sensitize tumors to immunotherapy.

Citing Articles

Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy.

Wang R, Dong X, Zhang X, Liao J, Cui W, Li W Int J Biol Sci. 2025; 21(3):958-973.

PMID: 39897033 PMC: 11781167. DOI: 10.7150/ijbs.103877.

Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade.

Stefan V, Weber D, Lang R, Kofler B Cancer Immunol Immunother. 2024; 74(1):23.

PMID: 39537934 PMC: 11561221. DOI: 10.1007/s00262-024-03867-3.

An Exogenous Ketone Ester Slows Tumor Progression in Murine Breast and Renal Cancer Models.

Ogbonna H, Roberts Z, Godwin N, Muri P, Turbitt W, Swalley Z Cancers (Basel). 2024; 16(19).

PMID: 39410010 PMC: 11476193. DOI: 10.3390/cancers16193390.

References

Klement R, Champ C, Otto C, Kammerer U . Anti-Tumor Effects of Ketogenic Diets in Mice: A Meta-Analysis. PLoS One. 2016; 11(5):e0155050. PMC: 4861343. DOI: 10.1371/journal.pone.0155050. View

Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S . Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood. 2023; 142(16):1359-1370. PMC: 11561539. DOI: 10.1182/blood.2023020485. View

Shimazu T, Hirschey M, Newman J, He W, Shirakawa K, Le Moan N . Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2012; 339(6116):211-4. PMC: 3735349. DOI: 10.1126/science.1227166. View

Brogdon J, Xu Y, Szabo S, An S, Buxton F, Cohen D . Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2006; 109(3):1123-30. DOI: 10.1182/blood-2006-04-019711. View

Marks P, Breslow R . Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007; 25(1):84-90. DOI: 10.1038/nbt1272. View

Puchalska P, Crawford P . Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017; 25(2):262-284. PMC: 5313038. DOI: 10.1016/j.cmet.2016.12.022. View

Ammirante M, Luo J, Grivennikov S, Nedospasov S, Karin M . B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010; 464(7286):302-5. PMC: 2866639. DOI: 10.1038/nature08782. View

West A, Mattarollo S, Shortt J, Cluse L, Christiansen A, Smyth M . An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res. 2013; 73(24):7265-76. DOI: 10.1158/0008-5472.CAN-13-0890. View

Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I . Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Sci Immunol. 2023; 8(81):eade4656. PMC: 10336890. DOI: 10.1126/sciimmunol.ade4656. View

10.

Gray J, Saltos A, Tanvetyanon T, Haura E, Creelan B, Antonia S . Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019; 25(22):6623-6632. PMC: 7234799. DOI: 10.1158/1078-0432.CCR-19-1305. View

11.

Hirschberger S, Strauss G, Effinger D, Marstaller X, Ferstl A, Muller M . Very-low-carbohydrate diet enhances human T-cell immunity through immunometabolic reprogramming. EMBO Mol Med. 2021; 13(8):e14323. PMC: 8350890. DOI: 10.15252/emmm.202114323. View

12.

Moj D, Britz H, Burhenne J, Stewart C, Egerer G, Haefeli W . A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol. 2017; 80(5):1013-1026. PMC: 6056765. DOI: 10.1007/s00280-017-3447-x. View

13.

Newman J, Verdin E . β-Hydroxybutyrate: A Signaling Metabolite. Annu Rev Nutr. 2017; 37:51-76. PMC: 6640868. DOI: 10.1146/annurev-nutr-071816-064916. View

14.

Horton J, Davidson M, Kurishima C, Vega R, Powers J, Matsuura T . The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019; 4(4). PMC: 6478419. DOI: 10.1172/jci.insight.124079. View

15.

Hui B, Lu C, Li H, Hao X, Liu H, Zhuo D . Inhibition of APOE potentiates immune checkpoint therapy for cancer. Int J Biol Sci. 2022; 18(14):5230-5240. PMC: 9461658. DOI: 10.7150/ijbs.70117. View

16.

Weintraub K . Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med. 2016; 22(1):8-10. DOI: 10.1038/nm0116-8. View

17.

Christiansen A, West A, Banks K, Haynes N, Teng M, Smyth M . Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A. 2011; 108(10):4141-6. PMC: 3054015. DOI: 10.1073/pnas.1011037108. View

18.

Zhao Y, Liu Z, Liu G, Zhang Y, Liu S, Gan D . Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1. Cell Metab. 2023; 35(10):1688-1703.e10. PMC: 10558089. DOI: 10.1016/j.cmet.2023.09.004. View

19.

Pili R, Quinn D, Hammers H, Monk P, George S, Dorff T . Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clin Cancer Res. 2017; 23(23):7199-7208. PMC: 5712266. DOI: 10.1158/1078-0432.CCR-17-1178. View

20.

Karagiannis F, Peukert K, Surace L, Michla M, Nikolka F, Fox M . Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19. Nature. 2022; 609(7928):801-807. PMC: 9428867. DOI: 10.1038/s41586-022-05128-8. View